

# Nancy F Olivieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336498/publications.pdf>

Version: 2024-02-01

40  
papers

3,631  
citations

430754

18  
h-index

360920

35  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. <i>The Lancet Global Health</i> , 2022, 10, e134-e141.	2.9	6
2	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). <i>EClinicalMedicine</i> , 2021, 31, 100693.	3.2	3
3	Oxidative status in the $\beta^2$ -thalassemia syndromes in Sri Lanka; a cross-sectional survey. <i>Free Radical Biology and Medicine</i> , 2021, 166, 337-347.	1.3	6
4	A "One-Stop" Screening Protocol for Haemoglobinopathy Traits and Iron Deficiency in Sri Lanka. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 66.	1.6	3
5	Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. <i>PLoS ONE</i> , 2019, 14, e0211942.	1.1	29
6	Headache: an important symptom possibly linked to white matter lesions in thalassaemia. <i>British Journal of Haematology</i> , 2019, 185, 541-548.	1.2	7
7	Iron status and anaemia in Sri Lankan secondary school children: A cross-sectional survey. <i>PLoS ONE</i> , 2017, 12, e0188110.	1.1	15
8	Improving Laboratory and Clinical Hematology Services in Resource Limited Settings. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 497-512.	0.9	4
9	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. <i>British Journal of Haematology</i> , 2015, 169, 887-898.	1.2	22
10	Treatment of heart failure in adults with thalassaemia major: response in patients randomised to deferoxamine with or without deferiprone. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 38.	1.6	47
11	Chelation use and iron burden in North American and British thalassaemia patients: a report from the Thalassaemia Longitudinal Cohort. <i>Blood</i> , 2012, 119, 2746-2753.	0.6	78
12	Treatment strategies for hemoglobin E beta-thalassaemia. <i>Blood Reviews</i> , 2012, 26, S28-S30.	2.8	15
13	Hb E/beta-thalassaemia: a common & clinically diverse disorder. <i>Indian Journal of Medical Research</i> , 2011, 134, 522-31.	0.4	37
14	Emerging insights in the management of hemoglobin E beta thalassaemia. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 155-157.	1.8	12
15	HbE/ $\beta^2$ -Thalassaemia: Basis of Marked Clinical Diversity. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 1055-1070.	0.9	34
16	Phenomenon of Pain In Thalassaemia: A Prospective Analysis by the Thalassaemia Clinical Research Network (TCRN). <i>Blood</i> , 2010, 116, 256-256.	0.6	0
17	Rates of Non-Transfusional Iron Accumulation (NTIA) In Hemoglobin E Thalassaemia. <i>Blood</i> , 2010, 116, 5147-5147.	0.6	1
18	Pulmonary Hypertension in Thalassaemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassaemia Clinical Research Network Longitudinal Cohort Study.. <i>Blood</i> , 2009, 114, 2016-2016.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	0.6	5
20	Renal Dysfunction in Thalassemia.. Blood, 2009, 114, 2008-2008.	0.6	1
21	Studies in haemoglobin E beta-thalassaemia. British Journal of Haematology, 2008, 141, 388-397.	1.2	103
22	Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. Blood, 2008, 112, 1880-1880.	0.6	0
23	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	0.6	0
24	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	0.6	0
25	Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. Blood, 2004, 104, 1685-1685.	0.6	1
26	A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. Blood, 2004, 104, 3193-3193.	0.6	17
27	Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. Blood, 2004, 104, 3613-3613.	0.6	0
28	Patients'™ health or company profits? The commercialisation of academic research. Science and Engineering Ethics, 2003, 9, 29-41.	1.7	60
29	Deferiprone and hepatic fibrosis. Blood, 2003, 101, 5089-5091.	0.6	18
30	Long-Term Trials of Deferiprone in Cooley's Anemiaa. Annals of the New York Academy of Sciences, 1998, 850, 217-222.	1.8	13
31	Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major. New England Journal of Medicine, 1998, 339, 417-423.	13.9	389
32	Iron-Chelating Therapy and the Treatment of Thalassemia. Blood, 1997, 89, 739-761.	0.6	971
33	Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. New England Journal of Medicine, 1995, 332, 918-922.	13.9	306
34	Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator. Journal of Clinical Pharmacology, 1994, 34, 944-949.	1.0	79
35	Iron overload cardiomyopathies: New insights into an old disease. Cardiovascular Drugs and Therapy, 1994, 8, 101-110.	1.3	128
36	Survival in Medically Treated Patients with Homozygous $\beta^0$ -Thalassemia. New England Journal of Medicine, 1994, 331, 574-578.	13.9	829

#	ARTICLE	IF	CITATIONS
37	Pain Perception and Effectiveness of the Eutectic Mixture of Local Anesthetics in Children Undergoing Venipuncture. <i>Pediatric Research</i> , 1992, 32, 520-523.	1.1	35
38	Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. <i>American Journal of Hematology</i> , 1992, 41, 61-63.	2.0	34
39	Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 294-298.	2.3	51
40	Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. <i>New England Journal of Medicine</i> , 1985, 312, 1600-1603.	13.9	269